Suppr超能文献

与澳大利亚初级医疗保健相比,社区药房中接受阿片类激动剂治疗的丙型肝炎患者的治疗成本效益

Cost-Effectiveness of Treating Hepatitis C in Clients on Opioid Agonist Therapy in Community Pharmacies Compared to Primary Healthcare in Australia.

作者信息

Ginnane Joshua F, Scott Nick, Radley Andrew, Dillon John F, Hellard Margaret, Doyle Joseph

机构信息

Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.

School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

出版信息

J Viral Hepat. 2025 Apr;32(4):e14015. doi: 10.1111/jvh.14015. Epub 2024 Oct 23.

Abstract

Meeting the World Health Organisation 2030 target of treating 80% of people with hepatitis C virus (HCV) in Australia requires accessible testing and treatment services for at-risk populations. Previous clinical trials, including those in Australia, have demonstrated the efficacy of outreach programmes to community pharmacies offering opioid agonist therapy (OAT). This analysis evaluates the potential cost-effectiveness of introducing an outreach programme in community pharmacies. Using a decision analytic model, we estimated the impact of adding a temporary hepatitis C outreach and treatment programme in community pharmacies to the standard treatment pathway available through general practice. We compared the expected number of tests, diagnoses, cures and costs occurring through the addition of this outreach and treatment programme to those expected through general practice alone over a 12-month time horizon. We examined costs from the perspective of the health system and conducted one-way and probabilistic sensitivity analyses to assess uncertainty in model parameters and test key assumptions. In the model adding the outreach programme pathway increased the number of tests from 4178 to 8737, the number of diagnoses from 615 to 1285 and the number of cures from 223 to 777 among people on OAT over a 12-month period. Each additional cure achieved through the addition of the outreach programme was estimated to incur $48,964 (AUD 2023) to the health system, with > 85% of these costs attributable to medication and dispensing expenses. The average cost per cure was estimated to be $49,152 through routine care and $49,018 in the outreach programme. Although outreach models of care incur large upfront costs, they can capture otherwise unreached populations and result in comparable or favourable cost per cure, due to higher levels of engagement and lower rates of loss to follow-up.

摘要

要实现世界卫生组织设定的到2030年在澳大利亚治疗80%丙型肝炎病毒(HCV)感染者的目标,就需要为高危人群提供可及的检测和治疗服务。此前包括在澳大利亚开展的临床试验已证明,向社区药房提供阿片类激动剂疗法(OAT)的外展项目具有有效性。本分析评估了在社区药房引入外展项目的潜在成本效益。我们使用决策分析模型,估计了在社区药房增加一个临时丙型肝炎外展和治疗项目对通过全科医疗提供的标准治疗途径的影响。我们比较了在12个月时间范围内,增加该外展和治疗项目后预期的检测、诊断、治愈数量及成本与仅通过全科医疗预期的情况。我们从卫生系统的角度审视成本,并进行了单向和概率敏感性分析,以评估模型参数的不确定性并检验关键假设。在模型中,增加外展项目途径使接受OAT治疗的人群在12个月内的检测数量从4178例增加到8737例,诊断数量从615例增加到1285例,治愈数量从223例增加到777例。估计通过增加外展项目每多实现一例治愈,卫生系统要花费48,964澳元(2023年澳元),其中超过85%的成本归因于药物和配药费用。通过常规护理每治愈一例的平均成本估计为49,152澳元,在外展项目中为49,018澳元。尽管外展护理模式会产生大量前期成本,但由于参与度较高且失访率较低,它们能够覆盖原本无法触及的人群,并产生相当或更优的每治愈成本。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dd1/11897583/135d540a9f01/JVH-32-0-g003.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验